Cancer cells upregulate PD-L1 expression in response to inflammatory cytokines such as interferon-γ (IFN-γ), in a process known as “adaptive immune resistance,” and can be predictive of successful patient response rates to ICI (4, 5). The gene discussed is IFNG; the disease is cancer.